《大行報告》一表列出富瑞預測下週五或有機會獲宣佈「染藍」股份名單
就恆生指數服務公司將於下週五(20日)公佈檢討結果,富瑞發表報告測恆指首季檢討結果,列出該行預測或有機會「染藍」股份名單,該行料將潛在3至4只股份可獲「染藍」:
料機會較高股份│一旦被納入恆指成份股,潛在被動資金流入預測
協鑫科技(03800.HK│1.07億美元
中芯國際(00981.HK)│1.57億美元
藥明康德(02359.HK)│7,500萬美元
中升控股(00881.HK)│6,400萬美元
該行料其他可能或獲納入的股份(但料機會較低)
龍源電力(00916.HK)
華潤電力(00836.HK)
海爾智家(06690.HK)
京東健康(06618.HK)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.